| Literature DB >> 31055720 |
Dániel Pécsi1, Nelli Farkas1,2, Péter Hegyi1,3,4, Péter Varjú1, Zsolt Szakács1, Anna Fábián4, Gábor Varga5, Zoltán Rakonczay6, Emese Réka Bálint6, Bálint Erőss1, József Czimmer7, Zoltán Szepes4, Áron Vincze8.
Abstract
In cases of difficult biliary cannulation, transpancreatic sphincterotomy (TPS) can be an alternative approach of biliary access. However, its success and safety profile have not been studied in detail. A systematic review and meta-analysis were performed to study the overall cannulation success and adverse events of TPS. These outcomes were also compared to other advanced cannulation methods. A systematic literature search was conducted to find all relevant articles containing data on TPS. Successful biliary cannulation and complications rates [post-ERCP pancreatitis (PEP), bleeding, and perforation rates] were compared in the pooled analyses of prospective comparative studies. The overall outcomes were calculated involving all studies on TPS. TPS was superior compared to needle-knife precut papillotomy (NKPP) and the double-guidewire method (DGW) regarding cannulation success (odds ratio [OR] 2.32; 95% confidence interval [CI] 1.37-3.93; and OR 2.72; 95% CI 1.30-5.69, respectively). The rate of PEP did not differ between TPS and NKPP or DGW; however, TPS (only retrospective studies were available for comparison) proved to be worse than needle-knife fistulotomy in this regard (OR 4.62; 95% CI 1.36-15.72). Bleeding and perforation rates were similar among these advanced techniques. There were no data about long-term consequences of TPS. The biliary cannulation rate of TPS is higher than that of the other advanced cannulation techniques, while the safety profile is similar to those. However, no long-term follow-up studies are available on the later consequences of TPS; therefore, such studies are strongly needed for its full evaluation.Entities:
Keywords: Cholangiopancreatography, endoscopic retrograde/adverse effects; Cholangiopancreatography, endoscopic retrograde/methods; Postoperative hemorrhage/etiology; Sphincterotomy, endoscopic/adverse effects; Sphincterotomy, endoscopic/methods
Mesh:
Year: 2019 PMID: 31055720 PMCID: PMC6704096 DOI: 10.1007/s10620-019-05640-4
Source DB: PubMed Journal: Dig Dis Sci ISSN: 0163-2116 Impact factor: 3.199
Summary of success rate and adverse events of transpancreatic sphincterotomy in published series
| Studies | Design | Number of patients in TPS group | Successful biliary cannulation | % | PEP | % | Bleeding | % | Perforation | % |
|---|---|---|---|---|---|---|---|---|---|---|
| Catalano et al. [ | RCT | 31 | 29 | 93.5 | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% |
| Cha et al. [ | RCT | 42 | 39 | 92.9 | 5 | 11.9% | NA | NA | NA | NA |
| Sugiyama et al. [ | RCT | 34 | 32 | 94.1 | 1 | 2.9% | 0 | 0.0% | 0 | 0.0% |
| Yoo et al. [ | RCT | 37 | 29 | 78.4 | 4 | 10.8% | 2 | 5.4% | 0 | 0.0% |
| Zang et al. [ | RCT | 73 | 70 | 95.9 | 5 | 6.8% | 1 | 1.4% | 0 | 0.0% |
| Sum of RCTs | 217 | 199 | 91.7 | 16 | 7.4% | 3 | 1.7%a | 0 | 0.0%a | |
| Espinel-Diez et al. [ | Prospective | 125 | 117 | 93.6 | 4 | 3.2% | 6 | 4.8% | 1 | 0.8% |
| Kahaleh et al. [ | Prospective | 116 | 99 | 85.3 | 9 | 7.8% | 3 | 2.6% | 2 | 1.7% |
| Kim et al. [ | Prospective, sequential | 38 | 28 | 73.7 | 14 | 36.8% | 1 | 2.6% | 0 | 0.0% |
| Weber et al. [ | Prospective | 108 | 103 | 95.4 | 6 | 5.6% | 6 | 5.6% | 0 | 0.0% |
| Zou et al. [ | Prospective, sequential | 25 | 18 | 72.0 | NA | NA | NA | NA | NA | NA |
| Sum of prospective studies | 629 | 564 | 89.7 | 49 | 8.1%a | 19 | 3.4%a | 3 | 0.5%a | |
| Akashi et al. [ | Retrospective | 172 | 163 | 94.8 | 10 | 5.8% | 2 | 1.2% | 0 | 0.0% |
| Barakat et al. [ | Retrospective | 368 | 321 | 87.2 | 4 | 1.1% | 1 | 0.3% | 0 | 0.0% |
| Chan et al. [ | Retrospective | 53 | 36 | 67.9 | 2 | 3.8% | 1 | 1.9% | 0 | 0.0% |
| de-la-Morena-Madrigal et al. [ | Retrospective | 50 | 35 | 70.0 | 2 | 4.0% | 1 | 2.0% | 0 | 0.0% |
| de-la-Morena-Madrigal et al. [ | Retrospective | 78 | 75 | 96.2 | 5 | 6.4% | 4 | 5.1% | 4 | 5.1% |
| Esmaily et al. [ | Retrospective | 105 | 81 | 77.1 | 6 | 5.7% | 1 | 1.0% | 1 | 1.0% |
| Goff [ | Retrospective | 32 | 29 | 90.6 | 4 | 12.5% | 0 | 0.0% | 0 | 0.0% |
| Goff [ | Retrospective | 51 | 50 | 98.0 | 0 | 0.0% | 0 | 0.0% | 1 | 2.0% |
| Halttunen et al. [ | Retrospective | 262 | 255 | 97.3 | 23 | 8.8% | 4 | 1.5% | 0 | 0.0% |
| Horiuchi et al. [ | Retrospective | 48 | 46 | 95.8 | 1 | 2.1% | 0 | 0.0% | 0 | 0.0% |
| Huang et al. [ | Retrospective | 60 | 51 | 85.0 | 2 | 3.3% | 0 | 0.0% | 0 | 0.0% |
| Javia et al. [ | Retrospective | 20 | 15 | 75.0 | 1 | 5.0% | 0 | 0.0% | 0 | 0.0% |
| Kapetanos et al. [ | Retrospective | 34 | 29 | 85.3 | 1 | 2.9% | 1 | 2.9% | 0 | 0.0% |
| Katsinelos et al. [ | Retrospective | 67 | 67 | 100.0 | 15 | 22.4% | 0 | 0.0% | 0 | 0.0% |
| Lee et al. [ | Retrospective | 67 | 58 | 86.6 | 7 | 10.4% | 5 | 7.5% | 0 | 0.0% |
| Liao et al. [ | Retrospective | 108 | 99 | 91.7 | 4 | 3.7% | 2 | 1.9% | 0 | 0.0% |
| Lin [ | Retrospective | 20 | 18 | 90.0 | 3 | 15.0% | 1 | 5.0% | 0 | 0.0% |
| McGonigle et al. [ | Retrospective | 31 | 25 | 80.6 | 2 | 6.5% | 1 | 3.2% | 1 | 3.2% |
| Miao et al. [ | Retrospective | 36 | 35 | 97.2 | 2 | 5.6% | 0 | 0.0% | 0 | 0.0% |
| Miyatani et al. [ | Retrospective | 20 | 17 | 85.0 | 6 | 30.0% | 1 | 5.0% | 0 | 0.0% |
| Wang et al. [ | Retrospective | 140 | 116 | 82.9 | 16 | 11.4% | 2 | 1.4% | 0 | 0.0% |
| Wen et al. [ | Retrospective | 113 | 111 | 98.2 | 11 | 9.7% | 2 | 1.8% | 1 | 0.9% |
| Zhong et al. [ | Retrospective | 77 | 73 | 94.8 | 8 | 10.4% | 2 | 2.6% | 0 | 0.0% |
| Sum of all study | 2615 | 2343 | 89.6 | 183 | 7.1%a | 50 | 2.0%a | 11 | 0.4%a |
NA not applicable, TPS transpancreatic sphincterotomy
aCalculated from those studies where the rate of this adverse event was available
Risk of bias assessment of prospective, non-randomized, and retrospective studies with the Newcastle–Ottawa scale
S/1: Representativeness of the exposed cohort (transpancreatic sphincterotomy group compared to advanced cannulation technique group); S/2: Selection of the non-exposed cohort (advanced cannulation technique group); C/1: Comparability of cohorts on the basis of similar indications of procedure; C/2: Comparability of cohorts on the basis of age; E/1: Assessment of outcome (were blinded assessment executed?); E/2: Was follow-up long enough? (longer than 14 days); E/3: Adequacy of follow-up of cohorts (is any attrition of patients present?) Two studies are not comparing TPS to another advanced cannulation technique and are marked with an asterisk
Risk of bias assessment of RCTs with the Cochrane Collaboration risk of bias tool
1: Random sequence generation; 2: allocation concealment; 3: blinding of participants and personnel; 4: blinding of outcome assessment; 5: incomplete outcome data; 6: selective reporting; 7: other bias
Fig. 1Flow diagram of literature search
Characteristics of the studies included in the meta-analysis with the prophylactic measures to prevent post-ERCP pancreatitis (PEP)
| Study | Study design | Comparison | Sequential design | Form of publication | PPS use | Pharmacologic prevention |
|---|---|---|---|---|---|---|
| Cha et al. [ | RCT | DGW versus TPS | No | Abstract | NR | NR |
| Sugiyama et al. [ | RCT | DGW versus TPS | No | Full text | In all cases | Nafamostat |
| Yoo et al. [ | RCT | DGW versus TPS | No | Full text | No | No |
| Kim et al. [ | Prospective | DGW versus TPS versus NKPP | Yes | Full text | 2/27 (7%) in DGW group, 25/38 (66%) in TPS group, | No |
| Zou et al. [ | Prospective | DGW versus TPS versus NKPP | Yes | Full text | 14/63 (22%) in all patients compared, not reported separately in DGW/TPS groups | No |
| Catalano et al. [ | RCT | NKPP versus TPS | No | Full text | PPS in some patients | No |
| Zang et al. [ | RCT | NKPP versus TPS | No | Full text | No | No |
| Espinel-Diez [ | Prospective | NKPP versus TPS | No | Full text | No | No |
| Horiuchi et al. [ | Retrospective | NKF versus TPS | No | Full text | No | No |
| Katsinelos et al. [ | Retrospective | NKPP versus NKF versus TPS | No | Full text | PPS in some patients | Diclofenac and somatostatin in some patients |
| Lee et al. [ | Retrospective | NKF versus TPS | No | Abstract | No | Protease inhibitor |
| Wen et al. [ | Retrospective | NKF versus TPS | No | Abstract | NR | NR |
| Kahaleh et al. [ | Prospective | No | No | Full text | 29/116 (25%) of all cases | NR |
| Weber et al. [ | Prospective | No | No | Full text | No | NR |
PPS prophylactic pancreatic stent, RCT randomized controlled trial, DGW double-guidewire cannulation, TPS transpancreatic biliary sphincterotomy, NKPP needle-knife precut papillotomy, NKF needle-knife fistulotomy, NR not reported
Summary of the definitions of difficult biliary access, endoscopists’ experience, and centers’ case load in the studies included in the meta-analysis
| Study | Definitions of difficult biliary access | Endoscopist’s experience | Centers |
|---|---|---|---|
| Cha et al. [ | Randomization when PGW inserted unintentionally | NR | Multicenter study, possibly high-volume university centers |
| Sugiyama et al. [ | Unsuccessful biliary cannulation after 15 min or unintentional pancreatic duct cannulation more than three times | Seven endoscopists who had at least 3-year experience in the pancreaticobiliary team at the tertiary referral center, performed over 300 ERCPs per year, and was able to achieve selective deep cannulation in more than 90% of cases using standard techniques | 2052 ERCP in 3 years (1 high-volume center) |
| Yoo et al. [ | Unsuccessful biliary cannulation after 10 attempts or failure of biliary access after 10 min | One experienced endoscopist | 1 center, between January 2005 and September 2010, a total of 1893 ERCPs |
| Kim et al. [ | Unsuccessful biliary cannulation after 10 attempts | Two endoscopists with > 1000 ERCPs lifetime caseloads | > 150 ERCPs/year with native papilla during the study |
| Zou et al. [ | Unsuccessful biliary cannulation by more than two experts; failure of biliary access after 30 min or unintentional pancreatic duct cannulation more than five times | Four endoscopists > 200 ERCPs/year in the last 3 years | > 1000 ERCPs/year in the last 2 years |
| Catalano et al. [ | Unsuccessful biliary cannulation after 30 min and/or the pancreatic duct had been opacified multiple times | NR | > 1000 ERCPs/year in the center |
| Zang et al. [ | Unsuccessful biliary cannulation after 10 min and/or unintentional pancreatic duct cannulation more than five times | One endoscopist with > 350 ERCPs/year caseload | Center caseload NR, likely high-volume center based on study inclusion numbers |
| Espinel-Diez et al. [ | Unsuccessful biliary cannulation after five attempts | One endoscopist with > 200 ERCPs/year caseload | Numbers NR, high volume of therapeutic ERCPs, numbers not specified |
| Horiuchi et al. [ | Unsuccessful biliary cannulation after 15 min and/or the pancreatic duct had been opacified multiple times | Two endoscopists, no caseload data reported | 200 ERCPs/year approximately |
| Katsinelos et al. [ | Unsuccessful biliary cannulation after 10 attempts | One experienced endoscopist performed all procedures (> 300 ERCPs/year) | > 300 ERCPs/year in the study period for patients with a naïve papilla |
| Lee et al. [ | Repeated unintentional pancreatic duct cannulation within 5 min and/or unintentional pancreatic duct cannulation more than three times | One experienced endoscopist (> 150 therapeutic ERCPs/year) | One center |
| Wen et al. [ | NR | One experienced endoscopist | One center |
| Kahaleh et al. [ | Unintentional pancreatic duct opacification more than three times | All ERCPs were performed by two dedicated pancreaticobiliary endoscopists; both perform more than 500 ERCPs annually. | High-volume center |
| Weber et al. [ | Not defined | NR | High-volume center |
NR not reported, PGW pancreatic guidewire, ERCP endoscopic retrograde cholangiopancreatography
Late adverse events in the prospective studies, where longer-term follow-ups were reported
| Study | Study design | Length of follow-up | Type | Complications | PD stricture |
|---|---|---|---|---|---|
| Kim et al. [ | Prospective, observational | NR | NR | No | No chronic pancreatitis or ductitis from PD stenting |
| Catalano et al. [ | RCT | NR | Telephone contact and office visits | No | No |
| Kahaleh et al. [ | Prospective, observational | Median follow-up was 5 months (2–35) | Clinic visit and/or telephone interview by a nurse | No | No |
Studies without follow-up data are not shown
RCT randomized controlled trial, PD pancreatic duct, NR not reported
Fig. 2a Forest plot of cannulation success rate of transpancreatic sphincterotomy (TPS) versus double-guidewire technique (DGW) in prospective studies; b comparison of cannulation success rate of TPS versus needle-knife precut papillotomy (NKPP) in prospective studies; c comparison of cannulation success rate of TPS versus needle-knife fistulotomy (NKF) in available comparative retrospective studies
Fig. 3a Forest plot of post-ERCP pancreatitis (PEP) rate of transpancreatic sphincterotomy (TPS) versus double-guidewire technique (DGW) in prospective studies; b comparison of PEP rate of TPS versus needle-knife precut papillotomy (NKPP) in prospective studies; c comparison of PEP rate of TPS versus needle-knife fistulotomy (NKF) in available comparative retrospective studies
Fig. 4a Forest plot of bleeding rate after transpancreatic sphincterotomy (TPS) versus double-guidewire technique (DGW) in prospective studies; b comparison of bleeding rate after TPS versus needle-knife precut papillotomy (NKPP) in prospective studies; c comparison of bleeding rate after TPS versus needle-knife fistulotomy (NKF) in available comparative retrospective studies
Fig. 5a Forest plot of comparison of perforation rate after transpancreatic sphincterotomy (TPS) versus double-guidewire technique (DGW) in prospective studies; b comparison of perforation rate after TPS versus needle-knife precut papillotomy (NKPP) in prospective studies; c comparison of perforation rate after TPS versus needle-knife fistulotomy (NKF) in available comparative retrospective studies